All In Biotech

Investigational drug · Phase 2

Relma-cel

Also called: CAR, CD19-targeted Chimeric Antigen Receptor T Cells, B-cell maturation antigen directed chimeric antigen receptor -T cell, BCMA

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-Hodgkin Lymphoma, Large B-cell Lymphoma, Multiple Myeloma.

Phase 2

Last checked: Nov 19, 2026Latest source record: Aug 21, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

3

3 still active

All registered trials

21

Any phase or sponsor naming "Relma-cel"

First trial start

2021

Jan 13, 2021

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Relma-cel", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Non-Hodgkin Lymphoma
  • Large B-cell Lymphoma
  • Multiple Myeloma
  • Mantle Cell Lymphoma

Approved drugs for the same conditions: Multiple myeloma · Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Hematology and blood cancers

Largest trials

Live from ClinicalTrials.gov: studies naming "Relma-cel" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 55,806 on PubMed

Also in development for Non-Hodgkin Lymphoma

  • CC-99282BMS-986369, GolcadomidePhase 37 trials

    Bristol Myers Squibb · Lymphoma, Follicular, Large B-cell Lymphoma, Non-Hodgkin Lymphoma

  • XNW5004EZH2iPhase 37 trials

    Evopoint Biosciences Inc. · Relapsed/Refractory Peripheral T Cell Lymphoma, Advanced Prostate Cancer, Follicular Lymphoma, Grade 1

  • TacabrutidegBGB-16673Phase 36 trials

    BeOne Medicines (BeiGene) · Chronic Lymphocytic Leukemia, B-cell Malignancy, Small Lymphocytic Lymphoma

  • Rondecabtagene autoleucelLYL314Phase 32 trials

    Lyell Immunopharma, Inc. · Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma

  • GNC-038Phase 24 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · Non-hodgkin's Lymphoma, Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma

  • Zugocabtagene geleucelCTX112Phase 23 trials

    CRISPR Therapeutics AG · B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy

  • AZD3470Phase 22 trials

    AstraZeneca · Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma

  • CYT-0851Phase 21 trial

    Cyteir Therapeutics, Inc. · Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.